Nuclear medicine

#Blood cancer #Breast cancer #CAR T-cell therapy #Clinical trial #epilepsy #Gene mutation #Genetic profiling #HER2 #Japan #Lung cancer #Nuclear medicine #Theranostics #University College London #University of Oxford

DDW Highlights: 7 July 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, experts warned patients were being denied access to personalised cancer care. Cancer… Read More

#Podcasts

#Blood cancer #Breast cancer #CAR T-cell therapy #Clinical trial #epilepsy #Gene mutation #Gene therapy #Genetic profiling #HER2 #Japan #Lung cancer #Nuclear medicine #Theranostics #University College London #University of Oxford #University of Queensland

This week in Drug Discovery (29 June – 3 July) 

News round-up for 29 June – 3 July by Bruno Quinney, Content Team at DDW.  This week, experts warn patients are being denied access to personalised cancer care. Cancer research is a theme elsewhere, with findings emerging from studies into a CAR T-cell therapy, lung cancer and breast cancer.  The… Read More

#News

Patients receiving chemotherapy
#Nuclear medicine #Theranostics #University of Queensland

Patients denied personalised cancer care, study says 

Cancer patients are being denied access to a “game changer” method of treatment, a new study warns.  Health economists Dr Yufan Wang and Professor Haitham Tuffaha led a review into the value of theranostic nuclear medicine, an innovative frontier in cancer treatment, and concluded patients are being… Read More

#Cancer Research #News

#Cancer research #Medicines Discovery Catapult #Nuclear medicine #Radiopharmaceuticals #UK

Is the UK set to become a radiopharma leader?

The latest episode of the DDW ‘In Conversation With’ series is available to listen to below. This week, Bruno Quinney speaks to Dr Juliana Maynard, Head of Translational Imaging at Medicines Discovery Catapult. MDC recently announced a partnership with the UK National Nuclear Lab, and Maynard’s… Read More

#Cancer Research #Featured Podcasts #Podcasts

#Cancer research #Nuclear medicine #Radiopharmaceuticals #UK

UK project to develop ‘cutting edge’ radiopharmaceuticals 

A £19 million ($25 million) UK programme is set to power the recycling of nuclear materials to develop cutting edge treatments for cancer.  Led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), the project will use a radionuclide called lead-212 to create… Read More

#Cancer Research #News

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Prostate cancer #UK #ViiV Healthcare

DDW Highlights: 3 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, more effective treatments were found for both HIV and chronic wounds. Elsewhere, €40,000… Read More

#Podcasts

#ABPI #Bispecific Antibodies #Clinical trial #Follicular lymphoma #GLP-1 #HIV #National Institute for Health and Care Excellence (NICE) #Novo Nordisk #Nuclear medicine #Obesity #Prostate cancer #UK #ViiV Healthcare #Weight loss

This week in Drug Discovery (23 – 27 February) 

News round-up for 23 – 27 February by Bruno Quinney, Content Team at DDW.  This week in drug discovery, more effective treatments have been found for both HIV and chronic wounds. Elsewhere, €40,000 is up for grabs in prostate cancer research.  The top stories:   … Read More

#News

Female scientists conducting research on samples
#Nuclear medicine #Prostate cancer

EANM launches award for prostate cancer research 

The European Association of Nuclear Medicine (EANM) has launched an award for research in prostate cancer treatment.  The 2026 EANM Young Scientist Network Award, aiming to accelerate innovation in alpha radioligand therapy in prostate cancer, offers three prizes of €40,000 (Platinum), €20,000 (Gold) and €10,000 (Silver). … Read More

#Cancer Research #News

#Antimicrobial resistance (AMR) #Bacteria #Cancer research #CAR T-cell therapy #GSK #Gut microbiome #Lung cancer #Nuclear medicine #Oncology #Osteosarcoma #UK government

This week in Drug Discovery (17 – 21 November) 

News round-up for 17 – 21 November by Bruno Quinney, Content Team at DDW.  This week in DDW, research into bacterial species and diseases gets top billing. Elsewhere, vaccines could offer groundbreaking solutions to cervical and lung cancer.  The top stories:    Medication detrimental to gut microbiome,… Read More

#News

UK
#Cancer research #Nuclear medicine #UK government

UK set to transform nuclear materials into cancer therapies 

Nuclear materials recycled in the UK are set to be used to develop cutting-edge cancer treatments.  A new government-backed project, led by United Kingdom National Nuclear Laboratory (UKNNL) and Medicines Discovery Catapult (MDC), will use a radionuclide called lead-212 to create treatments known as Targeted Alpha Therapies. The project has… Read More

#Cancer Research #News

Radioactive containers
#Affibody #Nuclear medicine #Oncology #Preclinical investigations #Radiopharmaceuticals

Preclinical data shows efficacy of radio-therapeutic anti-HER2 agent

Affibody has shared the results of preclinical studies with its radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2-expressing metastatic disease. The data were presented at the Annual Congress of the European Association of Nuclear Medicine by investigator Yongsheng Liu in the Professor Tolmachev group, Uppsala University. Read More

#Cancer Research #News